San Francisco dog owners urged to stay alert amid coyote pupping season
Those at Golden Gate Park recently noticed park rangers educating dog owners about an incident over the past weekend.
Howling coyotes at Golden Gate Park near Lindley Meadows, a popular spot where dog owners walk and play with their pups. Brandon Hartstein and his dog Oden encountered a pack of coyotes in the area about a year ago.
"We were walking on a trail that's not too popular and all of a sudden, three coyotes just appeared and started kind of stalking us," said Hartstein.
Similar stories of coyote encounters are surfacing this year. Lauren Roche watched her dog get chased by coyotes.
"She was running along the grassy area and I was running in the path that doesn't have cars, and there were two coyotes that started chasing after her," said Roche.
"And I look over, wow, they're going so fast, and it was two coyotes chasing after her. Luckily, she was fast enough to outrun them, and I called her back over and they ended up going away."
Signs like these are posted in Golden Gate Park to warn people about these potential run-ins with coyotes. Experts say coyotes are just protective during pupping season and are not displaying unprovoked aggression. They say the best thing to do is to shorten the leash and walk in the other direction. Something Hartstein tried to do.
"We kept on walking away," said Hartstein. "I was making loud sounds trying to scare them off, and eventually we started running. Luckily, a biker came by and I flagged him down and he helped to chase them off."
Some dog owners have noticed coyotes getting bolder and becoming used to humans in their territory. They say with these canines all over the Bay Area, the key is to limit conflicts and coexist with each other.
"I just kind of try to adjust my way of living because it's part of where they live," said Roche. "I wouldn't have to adjust for someone coming into my home."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Dentists Reveal The Right Time To Brush Your Teeth In The Morning—And It's Not When You Think
Yes, you brush your teeth every morning, but could you be brushing at the wrong time? It turns out there is a correct time to brush, according to dentists. 'Brushing your teeth in the morning is not just about fresh breath — it is a crucial part of protecting your oral and overall health,' says Anjali Rajpal, DMD, the founder of Beverly Hills Dental Arts. In fact, there's a growing amount of research that shows your dental health goes beyond your teeth and gums. 'Good oral health is intricately tied into good overall health and wellness,' says Steven J Katz, DDS, MS, the president of the American Association of Endodontists. 'Brushing, flossing and regular dental visits protect not just your mouth, but your heart, lungs, brain and more.' Before you get out your toothbrush, use the following tips to maximize your dental routine and time your tooth-brushing perfectly. Should you brush before or after breakfast? Both dentists we talked to agreed that if you only brush once in the morning, it's best to do it right after you wake up — before you have anything to eat. 'In addition to getting rid of that horrible morning breath, it is important to brush your teeth in the morning to remove the plaque and bacteria that developed overnight,' says Dr. Katz. That's because when you're sleeping, your body doesn't produce as much saliva as it does when you're awake so there's no liquid in your mouth to rinse off bacteria throughout the night. 'If left on your teeth, it will lead to tooth decay and gum disease,' adds Dr. Katz. 'And if you breathe with your mouth open while you sleep — as opposed to breathing through your nose — brushing first thing in the morning is even more important, because breathing through your mouth dries out the oral tissues, reduces salivary flow and increases plaque build-up.' Brushing beforehand also 'coats your teeth with protective fluoride, hydroxyapatite, calcium phosphate or other minerals that may be in your preferred toothpaste,' says Dr. Rajpal. This 'protects your teeth from acid attacks when you eat breakfast, especially if it is something sugary or acidic, says Dr. Rajpal. Should you brush again after breakfast? Probably, but there are a few things to keep in mind so it's best to double-check with your dentist. 'It is not recommended if you have exposed roots, thin enamel or tooth sensitivity because frequent brushing could aggravate it,' says Dr. Rajpal. Research suggests it's also best to wait 30 minutes after eating or drinking, especially if you've had acidic coffee or juice. 'Brushing too soon after acid exposure can actually damage your enamel, which becomes temporarily softened,' says Dr. Rajpal. Lastly, you need to consider how you brush your teeth. 'The appropriate technique is crucial,' says Dr. Katz. 'Brushing too aggressively can lead to gum recession, erosion of the enamel and sensitivity. Speak to your dentist and/or hygienist about the appropriate brushing technique.' They may recommend using a soft-bristled brush with light pressure and avoiding abrasive toothpaste like some that contain baking soda, charcoal or whitening agents, according to Dr. Rajpal. If over-brushing is a concern for you and 'if you really want a clean, fresh mouth after breakfast or coffee but have already brushed before, try just rinsing instead with a refreshing natural or alcohol-free mouthwash,' says Dr. Rajpal. Should you also brush after lunch? 'For most people, brushing twice a day, morning and night, is enough to maintain good oral health,' says Dr. Rajpal. 'However, brushing after lunch can be a smart move if you are prone to cavities or gum disease; you have eaten something sticky, sugary or acidic; you are wearing braces, aligners, or other appliances that trap food; or you will not be able to brush again for many hours possibly due to a long work shift or travel.' How to do a better job of brushing your teeth Take your oral health care to the next level with these tips for brushing your teeth: Floss first. Dr. Katz recommends flossing before you brush your teeth. Research has found that people who floss first remove more plaque from between their teeth and have higher concentrations of fluoride in the plaque. Don't rush it. 'Most people brush for 30 to 45 seconds, but you need a full 2 minutes to properly clean all surfaces of every tooth,' says Dr. Rajpal. 'Try using a timer or a song to pace yourself.' Angle your toothbrush. 'Always hold your brush at a 45-degree angle toward the gumline — not flat against your teeth,' says Dr. Rajpal. 'This helps clean where plaque starts, right where the teeth and gums meet.' While you're at it, make sure you brush your tongue, too. If you go electric, buy the right one. 'A $3 manual toothbrush can outperform a $200 electric one if you are using proper technique, brushing long enough and being thorough,' says Dr. Rajpal. 'However, if you prefer, a good electric toothbrush often includes timers and pressure sensors to protect your gums.' Skip the rinse. 'After brushing, spit but don't rinse with water right away,' says Dr. Rajpal. 'This leaves fluoride or other toothpaste minerals on your teeth longer, allowing it to strengthen enamel more effectively.' Toss old brushes. 'Replace your toothbrush or electric brush head every 3 months — or sooner if the bristles are frayed,' says Dr. Rajpal. Store your current brush upright in open air and not enclosed in a case where bacteria can thrive, she adds. The bottom line Brush your teeth right before bed and right when you wake up and floss daily. See your dentist for regular checkups and don't ignore pain or sensitivity in your mouth. 'Nothing looks, functions or feels like our own teeth,' says Dr. Katz. 'Teeth are essential for speech, eating and our all-important smiles. In addition, maintaining healthy teeth leads to improved cardiovascular health and reduced risk of diabetes and enables better cognitive function. In short, keeping your natural teeth isn't just about comfort or cosmetics, it's an investment in your long-term well-being.' You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Yahoo
an hour ago
- Yahoo
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete response at six months with CD19 CAR-NK in combination with rituximab and a third WM patient has been enrolled in the study First study to demonstrate the potential for complete responses with a chemotherapy-free immunotherapy in late-stage WM patients validating the power of NK cells CULVER CITY, Calif., August 13, 2025--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. QUILT-106 (NCT06334991) is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone and in combination with rituximab in patients with relapsed or refractory (R/R) CD19⁺CD20⁺ B-cell NHL. The disease remains challenging to treat, and WM is considered incurable with existing treatment options, making novel immunotherapies an important avenue of exploration for potential effective treatments. In the first two evaluable patients with WM who were heavily pretreated, an entirely chemotherapy-free, immunotherapy regimen induced encouraging responses. Both patients tolerated the regimen with no significant toxicities. Notably, all infusions (including CAR-NK cells and cytokines) were administered in an outpatient setting. One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date. The open-label study sponsored by ImmunityBio and led by Dr. Glenda Gray, former President and CEO of the South African Medical Research Council (SAMRC) and current Chair of the Global Antibiotic Research and Development Partnership (GARDP), has enrolled 13 patients with NHL at three sites in South Africa. Of the patients enrolled so far, three have WM. Eligible study participants express CD19 and CD20, with active disease after ≥2 chemotherapy-based lines of treatment. All patients receive a lead-in cycle of CD19 CAR-NK cell monotherapy, followed by a 1-week safety observation pause, then a second cycle combining CD19 CAR-NK with rituximab. Key endpoints include safety/tolerability and objective response rate (ORR) by standard criteria. "The preliminary findings we have submitted for presentation at the American Society of Hematology annual meeting provides the first evidence that novel immunotherapy combinations without chemotherapy lymphodepletion can provide deep and durable remissions in WM even after multiple prior treatments," said Dr. Jackie Thomson, Wits University Donald Gordan Medical Center, Johannesburg, South Africa and the lead author of the paper. "Recruitment in this rare subset of lymphoma is ongoing to confirm these findings and to establish this chemo-free strategy as a viable treatment option for relapsed WM." ImmunityBio's CD19 CAR-NK Therapy CD19 CAR-NK is a targeted high-affinity natural killer cell therapy – an off-the-shelf, allogeneic NK cell line engineered to express a CD19-specific chimeric antigen receptor (CAR) and a high-affinity CD16 (FcγRIIIa 158V) receptor. This design enables dual anti-tumor mechanisms: direct CAR-mediated cytotoxicity and augmented antibody-dependent cellular cytotoxicity when paired with anti-CD20 monoclonal antibody rituximab. Combining CD19 CAR-NK cells with rituximab could thereby target CD19⁺/CD20⁺ lymphoma cells to enhance tumor cell killing. About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. View source version on Contacts InvestorsHemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 MediaSarah Singleton ImmunityBio, Inc. +1 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
2 hours ago
- CBS News
Students from Palisades High start new school at Santa Monica Sears building
After the Palisades Fire tore through their school campus, students from Palisades Charter High School will be starting a new school year at the Santa Monica Sears building. The January wildfire severely damaged parts of the school, leaving students to attend classes online for several weeks before relocating to the vacant Sears building on Colorado Avenue in April. The department store was outfitted with classrooms and learning spaces to allow students to finish the rest of their school year. The school received donations from the community, which included furniture, carpet, paint, air conditioning and internet service. Now, on the first day of school, students will be more familiar with their surroundings at the Sears building as they seek a sense of normalcy in the fallout of the devastating fire. As many as 500 students and 11 staff members lost their homes to the Palisades Fire, according to Principal Dr. Pamela Magee. "All of this is so important as we bring everybody back together and try to get back that stability and normalcy that we all need," she told CBS News Los Angeles. The project to relocate an entire high school should've taken years, Magee said. She said she hopes that the school will be able to relocate to its main campus by January. In June, Pali High students celebrated their graduation at the Hollywood Bowl. Students were able to celebrate their big accomplishment and cross the stage after enduring an unimaginable year. All three schools in the Palisades community were burned during the Jan. 7 wildfire. The Los Angeles Unified School District budgeted $600 million-plus towards the rebuilding of the three schools.
